The $6 central target is not an official published consensus; it is a simple average of individual, attributable targets. Recent and current targets include Evercore ISI at $15, JonesTrading at $8 (lowered from $13), Wells Fargo at $6, Ladenburg Thalmann at $6, Baird at $6, H.C. Wainwright at $5, Guggenheim at $5, Clear Street at $4.60, RBC Capital at $4, Chardan Capital at $4, and Barclays at $3. The resulting average is roughly $6.05, which rounds to $6. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock compares to others in the industry.
The dispersion is unusually wide. Bullish analysts argue the gene-editing platform and EDIT-401 data justify a premium, while cautious voices, including the Hold-rated RBC Capital and Barclays, emphasize execution risk and dilution. Independent aggregators show similar but not identical figures: S&P Global's survey points to an average near $6.10 across 13 analysts, while shorter-window averages range from about $5.20 to $7.20 depending on which targets and time period are included. Recent actions have leaned positive, with Wells Fargo upgrading the stock to Overweight and Guggenheim upgrading it to Buy in the second half of 2026.
EDIT last closed at $1.71 on November 19, 2026, near the lower end of a 52-week range of roughly $1.66 to $3.94. Reaching $6 would require a gain of about 250%, which is a very large move by any standard and far beyond a typical single-stage catalyst for a small-cap biotech.
The company reported third-quarter 2026 results on November 9, 2026, posting a net loss of about $23.4 million, or $0.15 per share, beating expectations, with revenue of roughly $10.4 million, up about 37% year over year. It ended the period with cash near $190 million and a market capitalization in the mid-$200-million range. A path to $6 would likely require a combination of positive EDIT-401 clinical data, continued cost discipline, and a broader re-rating of gene-editing stocks — not simply a single quarter of improvement.
Several factors could support a recovery. The company's financial losses have narrowed materially — a nine-month 2026 net loss of about $67 million versus roughly $154 million a year earlier — and its cash position has improved. Analysts at TD Cowen and Evercore ISI have cited promising EDIT-401 data and a strengthened cash runway as reasons for constructive ratings. Recent upgrades from Wells Fargo and Guggenheim, alongside target increases from Chardan Capital, indicate that sell-side sentiment has been firming even as the share price has declined.
The lead program addresses a large, underserved population in hyperlipidemia, and positive in vivo gene-editing data would validate the broader platform. As a high-beta (about 2.1) small-cap, EDIT could also benefit disproportionately if risk appetite in the biotechnology sector improves.
The obstacles are substantial. EDIT remains pre-commercial, with revenue derived almost entirely from collaborations, and it is still burning cash at a significant rate. Dilution is a persistent risk: shares outstanding grew by roughly 38% over the past year. A high short interest, estimated at over 20% of the float in some reports, adds volatility and reflects genuine skepticism.
Regulatory and clinical timelines for gene-editing therapies are long and uncertain, and competition from peers such as CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics is intense. If EDIT-401 data disappoint, or if the company needs to raise capital at depressed prices, the stock could remain under pressure regardless of analyst targets.
EDIT is trading below both its 50-day moving average near $2.54 and its 200-day moving average near $2.70, reflecting a damaged long-term trend. The 52-week high of $3.94 is the first major resistance zone, followed by the psychological $5.00 level, then the $6.00 area where several analyst targets cluster. On the downside, the 52-week low near $1.66 is the critical support level; a sustained break below it would undercut the bullish case.
Analyst price targets typically reflect a research horizon of roughly 12 months, though individual firms apply different assumptions, and a handful of targets in this set are older and may not yet reflect the latest data. Investors should watch EDIT-401 clinical updates and preclinical readouts, quarterly earnings and cash-burn trends, any financing or partnership announcements, analyst target revisions, and broader sector sentiment toward gene editing.
In my experience following volatile names like this, automated tools can provide an extra layer of discipline. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile small-cap like EDIT, this kind of automated monitoring can help traders spot shifting momentum and manage risk more efficiently than manual chart review. Traders can use the signals to discover opportunities, monitor existing positions, and identify changing trends. The system updates in real time, which is particularly useful when clinical or financing news hits suddenly.
Reaching $6 from $1.71 would require roughly a 250% advance, a very large move that would likely depend on a decisive positive catalyst such as compelling EDIT-401 data or a major partnership. The analyst range of about $3 to $15 illustrates how wide the range of credible outcomes is, with the average near $6 sitting far above the current price. Supportive factors — narrowing losses, a stronger cash position, and recent upgrades — are real but are offset by dilution risk, heavy cash burn, high short interest, and clinical uncertainty. The $6 level is best understood as an average of what analysts believe the stock could be worth, not a forecast of near-term direction.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EDIT saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 78 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 44 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 121 of 154 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 79%.
The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.596). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company which translates genome editing technology into a novel class of human therapeutics
Industry Biotechnology